Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Antiviral treatment for HBV lowers the risk for liver cancer and other complications and can prevent transmission.
A personalized approach to diagnosis and treatment is needed when viral hepatitis and fatty liver disease coexist.
Nearly 70% of prior HBV vaccine nonresponders produced adequate antibodies after successful HCV treatment.
Hepatocellular carcinoma among people with HCV fell after the debut of direct-acting antivirals, but cases are rising for other groups.
However, researchers saw little difference across racial groups in HBV treatment initiation among those who were eligible.
Generic drugs are cheaper and lead to better treatment compliance compared with brand-name drugs.
Hepatitis A and B declined in 2021, but new hepatitis C cases have doubled since 2014.
In 2022, fatty liver disease accounted for nearly a quarter of all liver cancer cases on the transplant waiting list.
About 40% of people worldwide are not aware that viral hepatitis is a leading cause of liver cancer.
Viral hepatitis could kill more people than malaria, tuberculosis and HIV combined if trends continue.
Most study participants achieved viral suppression with minimal changes in kidney function or bone density.
HBV vaccination is now recommended for all infants, children and adults.
Cancer survivors make awesome advocates, and the summer 2023 issue of Cancer Health profiles several inspiring figures.
Most people who stopped long-term nucleoside/nucleotide analogs did not need to restart treatment.
Accelerated progress is needed to achieve Cancer Moonshot goal of cutting the age-adjusted cancer death rate by at least 50% over 25 years.
Human papillomavirus and hepatitis B vaccines lower the risk of developing cancer.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.